Details
Stereochemistry | ACHIRAL |
Molecular Formula | C15H16N3S |
Molecular Weight | 270.373 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 1 |
SHOW SMILES / InChI
SMILES
CN(C)C1=CC2=C(C=C1)N=C3C=C(C)C(N)=CC3=[S+]2
InChI
InChIKey=RQNADZJRELIICT-UHFFFAOYSA-N
InChI=1S/C15H16N3S/c1-9-6-13-15(8-11(9)16)19-14-7-10(18(2)3)4-5-12(14)17-13/h4-8H,16H2,1-3H3/q+1
Molecular Formula | C15H16N3S |
Molecular Weight | 270.373 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/22923899
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22923899
Tolonium chloride (INN, also known as toluidine blue or TBO) is a phenothiazine that has been used as a hemostatic, a biological stain, and a dye for wool and silk. Tolonium chloride has also been used as a diagnostic aid for oral and gastric neoplasms and in the identification of the parathyroid gland in thyroid surgery. Toluidine blue has high affinity for acidic tissue components, thereby staining tissues rich in DNA and RNA. It has found wide applications both as vital staining in living tissues and as a special stain owing to its metachromatic property. Toluidine blue has been used in vivo to identify dysplasia and carcinoma of the oral cavity.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22923899
Curator's Comment: William Henry Perkin in 1856
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: DNA or RNA Sources: https://www.ncbi.nlm.nih.gov/pubmed/22923899 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Blutene Approved UseTreatment and prevention of excessive menstrual flow. |
|||
Diagnostic | Unknown Approved UseUnknown |
|||
Diagnostic | Unknown Approved UseUnknown |
|||
Diagnostic | Unknown Approved UseUnknown |
Doses
Dose | Population | Adverse events |
---|---|---|
2 mg/kg 1 times / day single, intravenous Studied dose Dose: 2 mg/kg, 1 times / day Route: intravenous Route: single Dose: 2 mg/kg, 1 times / day Sources: |
unhealthy, 27 years n = 1 Health Status: unhealthy Condition: Lipedema Age Group: 27 years Sex: F Population Size: 1 Sources: |
Other AEs: Edema... |
4 mg/kg 1 times / day single, intravenous (mean) Studied dose Dose: 4 mg/kg, 1 times / day Route: intravenous Route: single Dose: 4 mg/kg, 1 times / day Sources: |
unhealthy, adult n = 27 Health Status: unhealthy Age Group: adult Population Size: 27 Sources: |
Other AEs: Cardiac arrhythmia... |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Edema | 2 mg/kg 1 times / day single, intravenous Studied dose Dose: 2 mg/kg, 1 times / day Route: intravenous Route: single Dose: 2 mg/kg, 1 times / day Sources: |
unhealthy, 27 years n = 1 Health Status: unhealthy Condition: Lipedema Age Group: 27 years Sex: F Population Size: 1 Sources: |
|
Cardiac arrhythmia | 4 mg/kg 1 times / day single, intravenous (mean) Studied dose Dose: 4 mg/kg, 1 times / day Route: intravenous Route: single Dose: 4 mg/kg, 1 times / day Sources: |
unhealthy, adult n = 27 Health Status: unhealthy Age Group: adult Population Size: 27 Sources: |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT01330082
Examination of the oral cavity after the local application of Toluidine Blue dye (tolonium chloride)
Route of Administration:
Other
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 08:36:06 UTC 2023
by
admin
on
Sat Dec 16 08:36:06 UTC 2023
|
Record UNII |
P3Y6XJA2D1
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
P3Y6XJA2D1
Created by
admin on Sat Dec 16 08:36:06 UTC 2023 , Edited by admin on Sat Dec 16 08:36:06 UTC 2023
|
PRIMARY | |||
|
46992-32-9
Created by
admin on Sat Dec 16 08:36:06 UTC 2023 , Edited by admin on Sat Dec 16 08:36:06 UTC 2023
|
SUPERSEDED | |||
|
7084
Created by
admin on Sat Dec 16 08:36:06 UTC 2023 , Edited by admin on Sat Dec 16 08:36:06 UTC 2023
|
PRIMARY | |||
|
1442649-22-0
Created by
admin on Sat Dec 16 08:36:06 UTC 2023 , Edited by admin on Sat Dec 16 08:36:06 UTC 2023
|
SUPERSEDED | |||
|
1335281-20-3
Created by
admin on Sat Dec 16 08:36:06 UTC 2023 , Edited by admin on Sat Dec 16 08:36:06 UTC 2023
|
SUPERSEDED | |||
|
1258839-02-9
Created by
admin on Sat Dec 16 08:36:06 UTC 2023 , Edited by admin on Sat Dec 16 08:36:06 UTC 2023
|
SUPERSEDED | |||
|
430434-33-6
Created by
admin on Sat Dec 16 08:36:06 UTC 2023 , Edited by admin on Sat Dec 16 08:36:06 UTC 2023
|
SUPERSEDED | |||
|
100000084656
Created by
admin on Sat Dec 16 08:36:06 UTC 2023 , Edited by admin on Sat Dec 16 08:36:06 UTC 2023
|
PRIMARY | |||
|
2701
Created by
admin on Sat Dec 16 08:36:06 UTC 2023 , Edited by admin on Sat Dec 16 08:36:06 UTC 2023
|
PRIMARY | |||
|
SUB04911MIG
Created by
admin on Sat Dec 16 08:36:06 UTC 2023 , Edited by admin on Sat Dec 16 08:36:06 UTC 2023
|
PRIMARY | |||
|
87648
Created by
admin on Sat Dec 16 08:36:06 UTC 2023 , Edited by admin on Sat Dec 16 08:36:06 UTC 2023
|
PRIMARY | |||
|
56109-24-1
Created by
admin on Sat Dec 16 08:36:06 UTC 2023 , Edited by admin on Sat Dec 16 08:36:06 UTC 2023
|
PRIMARY | |||
|
99963-91-4
Created by
admin on Sat Dec 16 08:36:06 UTC 2023 , Edited by admin on Sat Dec 16 08:36:06 UTC 2023
|
SUPERSEDED | |||
|
366-14-3
Created by
admin on Sat Dec 16 08:36:06 UTC 2023 , Edited by admin on Sat Dec 16 08:36:06 UTC 2023
|
SUPERSEDED |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |